A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people

BMC Infectious Diseases

Ji-Yeon Hyeon⁴  Yong-Seok Jeong³  Sang Won Lee⁴  Geun-Ryang Bae²  Young Joon Park²  Kwangsook Park²  Yunhyung Kwon¹  Somin Lee⁴  Seoyeon Hwang⁴  Hye-Jin Kim³ 

[1] Current Address: Division of HIV/AIDS and TB Control, Center for Infectious Diseases Control, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju 363-951, Chungcheongbuk-do, Republic of Korea;Division of Vaccine Preventable Disease Control and Prevention, Center for Infectious Diseases Control, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju 363-951, Chungcheongbuk-do, Republic of Korea;Department of Biology Graduate School, Kyung Hee University, Seoul 130-701, Dongdaemon-gu, Republic of Korea;WHO Polio National Reference Laboratory, Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju 363-951, Chungcheongbuk-do, Republic of Korea

关键词: Inactivated polio vaccine;    Seroprevalence;    Neutralization antibody;    Poliovirus;   

Others  :  1173920
DOI  :  10.1186/s12879-015-0894-z

 received in 2014-12-01, accepted in 2015-03-12,  发布年份 2015

【 摘 要 】

Background

A worldwide poliomyelitis eradication program was initiated in 1988; however, strains of wild poliovirus (WPV) are still endemic in some countries. Until WPV transmission is eradicated globally, importation and outbreaks of WPV are alarming possibilities. This study is the first report to document the polio immunity after 2004, when an inactivated polio vaccine (IPV) was introduced in the Republic of Korea.

Methods

A total of 745 serum samples from randomly selected patients ranging from 6 to 84 years of age were used for neutralization tests, performed in the World Health Organization polio national reference laboratory.

Results

Among the 745 tested sera, 439 (58.9%) were seropositive and 19 (2.6%) were seronegative to all PV serotypes. In all age groups, PV3 showed the lowest level of seroprevalence, at 509 cases (68.3%), compared to 616 (82.7%) for PV1 and 685 (91.9%) for PV2. In the 6–10-year age group, which included IPV-immunized children, the highest seropositive rate was observed and the difference in seroprevalence between PV3 and other serotypes was the lowest compared to the other age groups immunized with oral PV vaccines (OPV). In addition, the seronegative rates of all three PV types in children aged 6–10 in this study were found to be lower than those in OPV-immunized children reported in a previous study from the Republic of Korea. Meanwhile, middle-aged subjects (41–60 years) had the lowest seroprevalence and geometric mean titer.

Conclusions

This study indicates a deficiency in immunity to PV in middle-aged individuals, and low seroprevalence to PV3 in all age groups. In addition, due to the ongoing risk of importing PV, middle-aged people should consider PV vaccination before visiting a PV-endemic country. Our findings provide data to assist those involved in deciding future national polio vaccination strategies for the maintenance of a polio-free status in Korea.

【 授权许可】

   
2015 Kim et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Savolainen-Kopra C, Blomqvist S: Mechanisms of genetic variation in polioviruses. Rev Med Virol 2010, 20:358-371.
• [2]Wimmer E, Hellen CU, Cao X: Genetics of poliovirus. Ann Rev Genet 1993, 27:353-436.
• [3]Bodian D: Emerging concept of poliomyelitis infection. Science 1955, 122:105-108.
• [4]Sabin AB: Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science 1956, 123:1151-1157.
• [5]Nathanson N: The pathogenesis of poliomyelitis: what we don’t know. Adv Virus Res 2008, 71:1-50.
• [6]Centers for Disease Control and Prevention (CDC): Global polio eradication initiative strategic plan, 2004 MMWR Morb Mortal Wkly Rep 2004, 53:107-108.
• [7]Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA: Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
• [8]Centers for Disease Control and Prevention (CDC): Apparent global interruption of wild poliovirus type 2 transmission MMWR Morb Mortal Wkly Rep 2001, 50:222-224.
• [9]Luo HM, Zhang Y, Wang XQ, Yu WZ, Wen N, Yan DM, et al.: Identification and control of a poliomyelitis outbreak in Xinjiang, China. N Engl J Med 2013, 369:1981-1990.
• [10]Jee YM, Cheon DS, Kim KS, Lee SH, Yoon JD, Lee SW, et al.: A seroprevalence study of poliovirus antibody among primary schoolchildren in Korea. Epidemiol Infect 2004, 132:351-355.
• [11]Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T: Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007, 25:7041-7046.
• [12]Kim HJ, Kang BH, Hwang SY, Lee SW, Cheon DS, Kim KS, et al.: Clinical and enterovirus findings associated with acute flaccid paralysis in the Republic of Korea during the recent decade. J Med Virol 2013, 86:1584-1589.
• [13]World Health Organization: Polio laboratory manual. 4th edition. WHO, Geneva, Switzerland; 2004.
• [14]Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H: Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro Surveill 2007, 12:E7-E8.
• [15]Weber B, Rabenau H, Cinatl J, Maass G, Doerr HW: Quantitative detection of neutralizing antibodies against polioviruses and non-polio enteroviruses (NPEV) using an automated microneutralization assay: a seroepidemiologic survey. Zentralbl Bakteriol 1994, 280:540-549.
• [16]Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW: Deficiency of immunity to poliovirus type 3: a lurking danger? BMC Infect Dis 2012, 12:24. BioMed Central Full Text
• [17]Joce R, Wood D, Brown D, Begg N: Paralytic poliomyelitis in England and Wales, 1985–91. BMJ 1992, 305:79-82.
• [18]Robbins FC: Poliomyelitis eradication: a continuing story. FASEB J 1994, 8:665-666.
• [19]Pírez MC, Olivera I, Diabarboure H, Montano A, Barañano R, Badía F, et al.: Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies. Vaccine 2009, 27:2689-2694.
• [20]World Health Organization (WHO): Outbreak of type-1 wild poliovirus in adults, Namibia, 2006 WklyEpidemiol Rec 2006, 81:425-430.
• [21]Centers for Disease Control and Prevention (CDC): Outbreaks following wild poliovirus importations—Europe, Africa, and Asia, January 2009–September 2010 MMWR Morb Mortal Wkly Rep 2010, 59:1393-1399.
• [22]Centers for Disease Control and Prevention (CDC): Progress toward interruption of wild poliovirus transmission—worldwide, January 2011–March 2012 MMWR Morb Mortal Wkly Rep 2012, 61:353-357.
• [23]World Health Organization (WHO): Transmission of wild poliovirus type 2: apparent global interruption Wkly Epidemiol Rec 2001, 76:95-97.
• [24]Affanni P, Veronesi L, Rizziero S, Bizzoco S, Bracchi MT, Tanzi ML: Status of immunity against poliomyelitis: a study among European and extra-European young immigrants living in Parma. Acta Biomed 2005, 76:157-163.
• [25]Diedrich S, Claus H, Schreier E: Immunity status against poliomyelitis in Germany: determination of cut-off values in international units. BMC Infect Dis 2002, 2:2. BioMed Central Full Text
• [26]Estívariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, et al.: Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012, 12:128-135.
• [27]Nates SV, Martinez LC, Barril PA, Ferreyra LJ, Giordano MO, Masachessi G, et al.: Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously. Viral Immunol 2007, 20:3-10.